Neumora Therapeutics (NMRA) Non-Current Assets (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Non-Current Assets of $443000.0 for Q1 2026, down 76.46% year-over-year from $1.9 million in Q1 2025, and down 13.14% quarter-over-quarter from $510000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Non-Current Assets (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Non-Current Assets history runs 5 years deep, the most recent figure standing at $443000.0 for Q1 2026.
- In Q1 2026, Non-Current Assets fell 76.46% year-over-year to $443000.0; the TTM figure through Mar 2026 stood at $2.6 million (down 82.39% YoY), while the FY2025 annual figure was $510000.0, down 82.52% from the prior year.
- Non-Current Assets for Q1 2026 stood at $443000.0, down from $510000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $38.3 million in Q4 2022, with the low at $443000.0 in Q1 2026.
- The 5-year median for Non-Current Assets is $3.4 million (2024), against an average of $8.3 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets tumbled 53.2% in 2023, then slumped 85.12% in 2025.
- Neumora Therapeutics' Non-Current Assets stood at $38.3 million in 2022, then sank by 53.2% to $17.9 million in 2023, then tumbled by 83.72% to $2.9 million in 2024, then plunged by 82.52% to $510000.0 in 2025, then slipped by 13.14% to $443000.0 in 2026.
- Business Quant data shows NMRA's Non-Current Assets at $443000.0 in Q1 2026, $510000.0 in Q4 2025, and $751000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 443,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 443,000.00 |
| Dec 31, 2025 | 510,000.00 |
| Sep 30, 2025 | 751,000.00 |
| Jun 30, 2025 | 916,000.00 |
| Mar 31, 2025 | 1.88 Mn |
| Dec 31, 2024 | 2.92 Mn |
| Sep 30, 2024 | 3.93 Mn |
| Jun 30, 2024 | 6.15 Mn |
| Mar 31, 2024 | 7.43 Mn |
| Dec 31, 2023 | 17.92 Mn |
| Sep 30, 2023 | 19.01 Mn |
| Dec 31, 2022 | 38.28 Mn |